Enimmune Corporation (TPEX:6564)
Taiwan · Delayed Price · Currency is TWD 17.95
-0.25 (-1.37%)
Mar 4, 2026, 1:40 PM CST
Enimmune Market Cap
Enimmune has a market cap or net worth of 1.31 billion as of March 3, 2026. Its market cap has decreased by -31.84% in one year.
Market Cap
1.31B
Enterprise Value
1.21B
Revenue
42.23M
Ranking
n/a
PE Ratio
n/a
Stock Price
17.95
Market Cap Chart
Since September 18, 2018, Enimmune's market cap has decreased from 1.33B to 1.31B, a decrease of -1.17%. That is a compound annual growth rate of -0.16%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 3, 2026 | 1.31B | -11.65% |
| Dec 31, 2025 | 1.49B | -17.27% |
| Dec 31, 2024 | 1.80B | -27.21% |
| Dec 29, 2023 | 2.47B | -38.63% |
| Dec 30, 2022 | 4.02B | 69.85% |
| Dec 30, 2021 | 2.37B | -11.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
| Sep 18, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GenMont Biotech Incorporation | 1.54B |
| Great Novel Therapeutics Biotech & Medicals | 1.52B |
| Abnova (Taiwan) | 1.52B |
| NeoCore Technology | 1.50B |
| Meribank Biotech | 1.34B |
| GeneReach Biotechnology | 1.15B |
| Lukas Biomedical | 1.12B |
| Level Biotechnology | 1.08B |